Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_assertion type Assertion NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_head.
- NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_assertion description "[These data indicate that quantity and lytic efficiency of CD16(+) lymphocytes are major factors for ADCC induction by trastuzumab, and confirm that breast cancer responses to short-term trastuzumab monotherapy may depend on involvement of the ADCC mechanism.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_provenance.
- NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_assertion evidence source_evidence_literature NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_provenance.
- NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_assertion SIO_000772 18089830 NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_provenance.
- NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_assertion wasDerivedFrom befree-20140225 NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_provenance.
- NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_assertion wasGeneratedBy ECO_0000203 NP758397.RAhKKAIhpV6UXfiGqlhlqe7VP5nfEIZOxOyfygBD69MPU130_provenance.